A Phase IIa Trial With Dose Optimization of OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-terminal (BET) Proteins, in Recurrent Glioblastoma Multiforme (GBM) Patients
Phase of Trial: Phase I/II
Latest Information Update: 07 Jun 2016
At a glance
- Drugs Birabresib (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors OncoEthix
- 07 Jun 2016 Results (n=12) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 17 Dec 2015 Status changed from active, no longer recruiting to discontinued, as reported by ClinicalTrials.gov.
- 04 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.